baber/WOPTO huggingface dataset:
Patent ES-538735-A0 (ES)
IPC: C01B33/20
Filed: 1984-12-18
Abstract: Silicophosphoaluminates are crystallized from a two-phase reaction mixture comprising sources of silicon oxide, aluminum oxide and phosphorus oxide and a suitable directing agent. The silicon, phosphorus and aluminum components of such silicophosphoaluminates may, optionally, be replaced with other elements in the plus 4, 5 and 3 valence states, respectively. The crystalline oxides so produced have ion exchange properties and are readily convertible to catalytically active material.
Patent ES-543742-A0 (ES)
IPC: C07H15/26
Filed: 1985-05-31
Abstract: Novel 1,4-dihydropyridines of the fomula   <IMAGE>   in which R1 and R2 each independently is hydrogen, C1-C4-alkyl, C1-C12-alkoxy, C1-C4-halogenoalkoxy, halogen, nitro, C1-C4-halogenoalkyl, C1-C4-halogenoalkylmercapto,   <IMAGE>  in which Z is oxygen or sulphur, and R4 and R5 each independently is hydrogen, C1-C4-alkyl, C1-C6-alkoxy, halogen, C1-C4-halogenoalkyl, C1-C4-halogenoalkoxy or nitro, or R1 and R2, together with 2 C atoms of the phenyl ring, form the ring   <IMAGE>   X is oxygen, sulphur or the radical NR6, R6 is a C1-C6-alkyl group, A is a C2-C10-alkylene group, it being necessary that at least two C atoms are located in the alkylene chain which connects the carbonyloxy group to X, and R3 is a monosaccharide or disaccharide moiety or a protected monosaccharide or disaccharide moiety, or pharmaceutically acceptable addition salts thereof, which exhibit positive inotropic activity and are useful in treating circulatory disorders.
Patent ES-551509-A0 (ES)
IPC: A61P9/12
Filed: 1986-01-31
Abstract: Compounds of the general formula (I)(R is H, alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl or CHO, R' and R<sup>2</sup> are independently halogen, alkyl, alkoxy, hydroxyl, cyano, nitro or -NR<sup>3</sup>R<sup>4</sup> where R<sup>3</sup> and R<sup>4</sup> are independently H or alkyl and R<sup>2</sup> may be H) and their salts have selective α<sub>2</sub>- adrenoreceptor antagonist action.The compounds may be prepared by amination of compounds of the general formula (II)(where R<sup>1</sup> and R<sup>2</sup> are as defined above and X is a leaving group)
Patent FI-844396-A0 (FI)
Inventor: MYKLEBUST EIRIK
IPC: B65D88/22
Filed: 1984-11-08
Abstract: The present invention relates to a flattened flexible container made ready for filling with bulk material, and method and means for making a container comprising a liner of impervious sheet in an outer container of strong load-bearing material. The liner and the outer container are folded longitudinally in the same way such that the liner is kept in position by having its folds or gussets everywhere placed in the corresponding folds or gussets of the outer container. Both the liner and the outer container may have a longitudinal gusset on each side which can have a width of up to 1/8 of the container's circumference. The manufacture can be carried out in an apparatus (8) in form of a box which is open in both ends and can be folded together. Its side walls consist of longitudinal parts (7) which are connected to each other and the roof (4) and bottom (5) of the apparatus (8) by means of pliable connecting means (6). The container according to the invention can be filled with bulk material without prior inflation at the filling site.
Patent FI-865121-A0 (FI)
Inventor: TARROUX PIERRE
IPC: H01F3/14
Filed: 1986-12-16
Abstract: For an assembly of differing discharge-lamps, for each lamp of the assembly, an ideal air-gap value is determined for the stabilising choke for this lamp, and on the basis of the ideal air-gap values thus determined, there are chosen a minimum air-gap at least approximately suitable for one or more lamps (A, B, C, D, G) of the assembly, a maximum air-gap at least approximately suitable for one or more other lamps (I) of the assembly, and at least one intermediate air-gap at least approximately suitable for one or more of the remaining lamps (E, F, H) of the assembly, so as to at least approximately cover the differing air-gap requirements. An assembly of stabilising chokes is produced comprising a first choke produced by means of first magnetic- circuit elements each forming the chosen minimum air-gap, a second choke produced by means of second magnetic-circuit elements each forming the chosen maximum air-gap and one or more intermediate chokes produced by means of the first and second magnetic-circuit elements to form the chosen intermediate air-gap(s) by combining the minimum and maximum air-gaps.
Patent FI-870154-A0 (FI)
Inventor: WARD JOHN W
IPC: C10G65/12
Filed: 1987-01-15
Abstract: A waxy hydrocarbon feedstock is converted into a product hydrocarbon of reduced normal paraffin content by either dewaxing or hydrodewaxing the feedstock in the presence of a dewaxing or hydrodewaxing catalyst under conditions such that the normal paraffin content of the feedstock is reduced by selectively converting waxy paraffins into lower molecular weight hydrocarbons. At least a portion of the effluent from the dewaxing or hydrodewaxing zone is then passed to a hydrocracking zone where it is contacted with a hydrocracking catalyst in the presence of hydrogen under conditions such that a further reduction in the normal paraffin content is effected. When the desired product is a lube oil base stock, the overall conversion of components in the feed boiling above about 345 DEG C (650 DEG F) to components boiling at or below about 345 DEG C (650 DEG F) that takes place in the dewaxing or hydrodewaxing step and the hydrocracking step combined is no more than about 20 volume percent, preferably no more than about 10 volume percent. When the desired product is a middle distillate, the overall conversion of feedstock constituents in the dewaxing or hydrodewaxing step and the hydrocracking step combined to components boiling below about 150 DEG C (300 DEG F) is no more than about 25 volume percent, preferably no more than about 15 volume percent.
Patent FI-895028-A0 (FI)
Inventor: NORELL MARIA
IPC: C01B11/02
Filed: 1989-10-23
Abstract: A process for production of chlorine dioxide by reacting in a reaction vessel an alkali metal chlorate, a mineral acid and methanol as a reducing agent in proportions to generate chlorine dioxide in a reaction medium maintained at a temperature from about 50 DEG C to about 100 DEG C and at an acidity within the interval from about 2 to about 11 N and subjected to a subatmospheric pressure. Thereby water is evaporated and a mixture of chlorine dioxide, water vapour and gaseous by-products is withdrawn from an evaporation region in the reaction vessel. The alkali metal sulphate is precipitated in a crystallization region in the reaction vessel. The content of formic acid in the reaction vessel is increased by addition of formic acid to a content of formic acid exceeding about 0.3 M. The gaseous by-products are condensed to obtain formic acid and the content of formic acid in the reaction vessel is increased by recirculation of the condensate.
Patent FI-903360-A0 (FI)
Inventor: BEUTLER SCOTT D
IPC: H04M1/02
Filed: 1990-07-04
Abstract: The hinge is for a foldable telephone having a body portion and a flip element portion, the hinge being capable of maintaining the flip element portion in at least two positions of rotation relative to the body portion. A first position is parallel to a front surface plane of the body portion and a second position at an obtuse angle to the front surface plane of the body portion, the hinge comprising a first cylindrical hinge shaft rotatably coupling the flip element portion to the body portion. - First and second recesses are disposed in the wall of the first cylindrical hinge shaft, the first and second recesses having planar bottom surfaces, the plane of the planar bottom surface of the first recess intersecting the plane of the planar bottom surface of the second recess an acute angle. A first cam is disposed within the flip element portion and having at least one flat surface which contacts the planar bottom surface of the first recess when the flip element portion is in the first position and which contacts the planar bottom surface of the second recess when the flip element portion is in the second position.
Patent FI-914996-A0 (FI)
Inventor: BERTELLI GUIDO
IPC: C08L23/00
Filed: 1991-10-23
Abstract: Concentrate of a flame retardant additive, in the form of nonextruded particles, each one comprising:   A) a matrix of a nonextruded, as polymerized particle, preferably spheroidal, of a polymer or copolymer of olefins having porosity greater than or equal to 15%, expressed as a percent of the void volume on the total volume of the particle, B) the product of reaction between bismuth or antimony trichloride or tribromide, or their mixtures, and one or more amines; wherein said product (B) is made "in situ" and deposited on the surface of the matrix and inside the pores thereof. d
Patent FI-920261-A0 (FI)
Inventor: KINNEY WILLIAM ALVIN
IPC: C07C229/06
Filed: 1992-01-21
Abstract: ((2-Amino-3,4-dioxo -1-cyclo-buten-1-yl) amino)alkyl)acid derivs. of formula (I) and their salts are new: R1 = H, 1-6C alkyl or 7-12C phenylalkyl; R2 = H, 1-6C alkyl, 2-6C alkenyl or 7-12C phenylalkyl; or R1 + R2 = Z; Z = -CH2CH2-, -CH2C(R6)(R7)CH2- or -CH2C(R8)(R9)-C(R10)(R11)CH2-; R6, R8, R10 = H, 1-6C alkyl or OH; R7, R9, R11 = H or 1-6C alkyl; A = 1-6C alkylene or 2-6C alkenylene; X = CO2R3, P(O)(OR4)(OR5), 3,5-dioxo-1,2,4-oxadiazolidin-2-yl or 5-tetrazolyl; R3 = H or 1-6C alkyl; R4, R5 = H or 1-6C alkyl. Also claimed are intermediates of formula (XII) and their salts: X2 = CN, COOR14, -PO(OR15)(OR16), 3,5-dioxo-1,2,4-oxadiazolidinyl or opt. protected 5-tetrazolyl; R12 = alkoxy or aralkoxy leaving gp.; R13 = H, 1-6C alkyl, 2-6C alkenyl, 7-12C phenylalkyl or NHP; R14 = H, 1-6C alkyl or carboxyl protecting gp.; R15, R16 = H or 1-6C alkyl; P = amino protecting gp.
Patent FI-932025-A0 (FI)
Inventor: MARCUS FRANK
IPC: C07K14/42
Filed: 1993-05-05
Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles. Cells bearing a mannose receptor or asialoglycoprotein receptor are capable of being infected with HCV, and supporting culturing of the virus.
Patent FI-934995-A0 (FI)
Inventor: VATANEN HARRI TAPANI
IPC: G07F7/08
Filed: 1993-11-11
Abstract: A method and apparatus for effecting user-initiated communications, such as payment transactions, between user-accessible data terminal equipment communicatingly linkable with a mobile telephone exchange and at least one service provider, wherein each user or subscriber has a service card that is uniquely associated with that system subscriber, preferably employs a dedicated network to which the mobile exchange is connected at one end of the network and the service provider is connected at another end. The user's identity is locally authenticated before a communications connection through the network is provided, and user access rights to particular services of the service provider are determined in a database at the service provider end of the network. The invention is particularly well suited to the use of a SIM-card in a GSM-network to provide secure communications in an environment demanding high data security.
Patent FI-940201-A0 (FI)
Inventor: BERGE ARVID
IPC: C08F12/00
Filed: 1994-01-14
Abstract: PCT No. PCT/NO92/00123 Sec. 371 Date Apr. 22, 1994 Sec. 102(e) Date Apr. 22, 1994 PCT Filed Jul. 15, 1992 PCT Pub. No. WO93/02112 PCT Pub. Date Feb. 4, 1993Process for producing a dispersion, wherein dispersed slightly crosslinked polyvinyl seed particles are swollen with an ionizing liquid, said seed particles containing covalently linked ionizable groups causing a swelling of the seed particles by the ionizing liquid to form a dispersion of droplets, wherein the resulting droplets after the swelling have a volume which is at least five times that of the seed particles. Said ionizing liquid may be or contain a polymerizable monomer or be charged with such a monomer. Polymerization of the monomers is effected in the droplets during or after the swelling, to form polymer particles.
Patent FI-941432-A0 (FI)
Inventor: UNGARELLI FABRIZIO
IPC: C08B37/00
Filed: 1994-03-28
Abstract: A process for the synthesis of semi-synthetic glycosaminoglycans of general formula III <CHEM> is described in which one of the saccharide units characteristic of glycosaminoglycans with heparin or heparan structure, more specifically that of  alpha -L-iduronic-2-O-sulfate acid, has undergone a structural modification, entirely or in part, with transformation into  alpha -L-galacturonic acid substituted in position 3 with nucleophilic radicals of general formula II <CHEM> Said process is carried out by treating glycosaminoglycans with heparin or heparan structure by means of a nucleophilic reagent in alkaline medium.
Patent FI-946082-A0 (FI)
Inventor: BUSCH FRANK ROBERT
IPC: A61K31/56
Filed: 1994-12-23
Abstract: PCT No. PCT/US93/02812 Sec. 371 Date Dec. 20, 1994 Sec. 102(e) Date Dec. 20, 1994 PCT Filed Apr. 2, 1993 PCT Pub. No. WO94/00479 PCT Pub. Date Jan. 6, 1994Processes for the synthesis of tigogenin beta-O-cellobioside heptaalkanoate which is an intermediate for the known hypo-cholesterolemic agent tigogenin beta-cellobioside. The process comprises reacting  alpha -cellobiosyl bromide heptaalkanoate and  beta -tigogenin in the presence of zinc fluoride or zinc cyanide under conditions capable of forming said tigogenyl  beta -O-cellobioside heptaalkanoate. The analogous preparations of hecogenin  beta -O-cellobioside heptaalkanoate 11-ketotigogenin  beta -O-cellobioside heptaalkanoate, and diosgenin  beta -O-cellobioside heptaalkanoate are also disclosed. The process provides both high  beta -anomeric selectivity and high yields.
Patent FI-970857-A0 (FI)
Inventor: WEID HELMUT
IPC: A01D34/73
Filed: 1997-02-28
Abstract: A thread cutter driven by an electric motor has a guiding stem (16) linked by a horizontal swivelling joint (18) to the thread cutter housing. A pedal trigger (46) allows locking means (42, 44) that determine the angular position of the stem in relation to the housing and that are designed as a toothed ring or tooth segment to be uncoupled. A spring (52) presses the pedal trigger into the coupling position in which the locking teeth of the locking means engage each other. When the foot rest is pressed down, the thread cutter remains in its stable support position, in which it rests on its roller (10) and on a bow that extends forwards and acts as a spacer and a skid (12). This prevents the apparatus from toppling over backwards when the foot rest is actuated, so that the stem may be adjusted without the need for additionally retaining the apparatus.
Patent FI-971785-A0 (FI)
Inventor: DEVRIES KEITH M
IPC: C07D498/04
Filed: 1997-04-25
Abstract: This invention relates to a process for preparing the compound having formula (I) which comprises i) heating the compound of formula (VII) wherein R<3> is R<4> or benzyl and R<4> is R<5>C(=O), R<5>OC(=O) or R<5>SO2 wherein R<5> is (C1-C6)alkyl or (C6-C10)aryl(C1-C6)alkyl; at an elevated temperature in the presence of a base with the proviso that when R<3> in the resultant product is R<4> said product is ii) further treated with an aqueous mineral acid at an elevated temperature followed by iii) treatment of the product of ii) with a) a benzylating agent in the presence of a base or b) benzaldehyde in the presence of a reducing agent and an acid.
Patent IL-86735-A0 (IL)
Title: Doxazosin as an anti-atherosclerosis agent
IPC: A61K31/505
Filed: 1988-06-14
Abstract: This invention relates to the use of doxazosin or a pharmaceutically acceptable acid addition salt thereof as an agent for retarding the development of atherosclerosis in a mammal, especially for reducing atherosclerotic plaque involvement and for retarding and reducing both the fibrosis and lipid deposition of developing atherosclerotic plaques associated with atherosclerosis.
Patent AU-PM766694-A0 (AU)
Title: Ring modified gibberellin compounds, and preparation and use thereof
IPC: A01N43/08
Filed: 1994-08-25
Abstract: PCT No. PCT/AU95/00528 Sec. 371 Date May 8, 1997 Sec. 102(e) Date May 8, 1997 PCT Filed Aug. 25, 1995 PCT Pub. No. WO96/06090 PCT Pub. Date Feb. 29, 1996Ring D-modified gibberellin compounds are effective in promoting or inducing a desired tissue morphology and/or physiological state in plants, giving effects such as growth retardation or inhibition and inhibition of floral development.
Patent AU-PR951101-A0 (AU)
Title: Method of treatment
IPC: A61K31/7068
Filed: 2001-12-13
Abstract: The invention relates generally to treatment of muscle pain and/or fatigue and to methods of treatment of side effects of statin therapy which involve the administration of uridine, biological precursors or derivatives or uridine or salts, esters, tautomers or analogues thereof, which are collectively referred to as uridine related compounds. The invention is also directed to compositions, uses and combination packs or kits related to the treatment method.
Patent FI-20085526-A0 (FI)
Inventor: PYKAELAEINEN NINA
Filed: 2008-05-30
Abstract: The invention relates to a process for producing a pigment product from a cellulose derivative. According to the invention, a selected cellulose derivative containing at least one OH group is crosslinked by using a hydroxyl-active crosslinker to form a substantially insoluble pigment product. Further, the invention relates to the corresponding product and to the use of the product.
Patent IL-107185-A0 (IL)
Title: 25-Carboxylic acid derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
IPC: A61P3/02
Filed: 1993-10-05
Abstract: New 25-carboxylic acid derivatives of general formula I,    <IMAGE>  (I)  R19 and R19a each mean a hydrogen atom or together form an exocyclic methylene group, R21 and R21a independently of one another mean a hydrogen atom, a chlorine or fluorine atom, an alkyl group with 1 to 4 carbon atoms, together a methylene group, together with quaternary carbon atom 20 mean a 3-7 membered, saturated or unsaturated carboxylic ring, Y preferably means a derivatized carboxyl radical, and the other substituents have the meanings indicated in the description as well as process for their production, are described. The new compounds have vitamin D activity as well as proliferation-inhibiting and cell-differentiating effects and are suitable for the production of pharmaceutical agents.
Patent IL-108957-A0 (IL)
Title: A system for implanting an image into a video stream
IPC: H04N9/74
Filed: 1994-03-14
Abstract: A system and method which mixes images, such as an advertisement, with a video stream of action occurring within a relatively unchanging space, such as a playing field, is disclosed. The system utilizes a model of the background space to change the video stream so as to include the image at some location within the background space. It includes a video frame grabber and an image implantation system. The frame grabber grabs a single frame of the video signal at one time. The image implantation system typically implants the grabbed image into the frame onto a predefined portion of a preselected one of the surfaces of the background space if the portion is shown in the frame. To determine the location of the portion to have implantation, the image implantation system includes a unit for receiving a) a flat model of the fixed surfaces and b) an image mask indicating the portion of the flat model onto which the image is to be mixed. Via the model, the image implantation system identifies if and where the portion is shown in the frame.
Patent IL-125104-A0 (IL)
Title: Agent for prophylaxis and treatment of diabetic complications
IPC: A61K31/4164
Filed: 1996-12-24
Abstract: The present invention relates to an agent for the prophylaxis and treatment of diabetic complications comprising, as an active ingredient, 4-Ä alpha -hydroxy-2-methyl-5-(1-imidazolyl)benzylÜ-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for the prophylaxis and treatment of diabetic complications comprising administering an effective amount of this compound. The medicament of the present invention is useful for the prophylaxis and treatment of diabetic complications, namely, diabetic neuropathy, nephropathy, ophthalmopathy, arteriosclerosis and the like. The action of the drug is long-lasting for very small doses and a single administration a day is sufficient.
Patent IL-126329-A0 (IL)
Title: Synthesis of beta-lactam antibacterials using soluble side chain esters and enzyme acylase
IPC: C07D501/06
Filed: 1997-07-15
Abstract: Disclosed is a process for the synthesis of  beta -lactam antibacterials using soluble side chain esters in the presence of enzyme acylase. Also disclosed are novel esters useful as reactants in said process.
Patent IL-127586-A0 (IL)
Title: Dose setting device
IPC: A61M5/172
Filed: 1997-06-09
Abstract: The present invention relates to a drug delivery device wherein a dose to be apportioned from a cartridge is set by changing the relative position of co-operating dose setting elements (3, 5) and is injected by pressing a button (5) until this button abuts a stop (6). By operation of count up (7) or count down (8) buttons the dose is set and read into an electronic circuit (9) comprising a microprocessor and the dose setting movement of the dose setting elements relative to each other is performed by a motor (11) controlled by the circuit in accordance with the read in dose. The set dose is shown on a display (10). The motor (11) is further controlled to perform certain movements of the piston rod (3) so as retraction of this rod when a cartridge (1) is going to be changed an advancing of the piston rod to abutment with the piston (2) after the cartridge has been changed and further to advance this piston to expel air from the cartridge.
Patent IL-135251-A0 (IL)
Title: Stand alone biometric identification system
IPC: G06T7/00
Filed: 1998-09-25
Abstract: A distributed biometric identification system incorporates stand-alone workstations. The system generally includes a plurality of stand-alone workstations capable of communicating with a central server remotely located from the workstations. The workstations receive input biometric data, such as fingerprint and photographic data, and compares that data to biometric data stored in the workstation. The workstation compares the input biometric data with stored biometric data to determine whether any of the stored biometric data matches the input biometric data. The results of the comparison are provided to the workstation screen. Workstation mobility is improved by housing the workstation in a self-contained, compartmentalized carrying case. Workstation mobility may be even further enhanced by housing the workstation in a so-called lunchbox configuration having a main body, a front panel hinged to the main body, and a back panel hinged to the main body. The front and back panels each have a stowed position adjacent the main body, and a deployed position away from the main body. When the panels are in their stowed positions, the workstation (i.e., main body, front panel, and back panel) is a compact, portable unit.